Pharmaceuticals, Biotechnology and Life Sciences
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the…
Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription…
Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical…
– RP1 plus nivolumab generated robust responses in both injected and non-injected lesions – – Deep/visceral injections, including into the…
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year…
First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)…